Protagonist Logo. Click to navigate to a home page

Drug Discovery Chemistry

April 23-27, 2017 12:00 PM ET

San Diego, CA, Sheraton San Diego Hotel and Marina United States


Presentation: Biomarker Discovery and Development of PTG-200, an Oral Peptide Antagonist of IL-23 Receptor
Meeting: 8th Annual Inflammation Inhibitors: Small Molecule Approaches for Oral-based Therapeutics
Presenter: Larry Mattheakis, Ph.D., Vice President, Biology, Protagonist Therapeutics 

Date and Time: 10:35 am PT, Monday April 24

Presentation: Discovery & Development of PTG-100, an Oral Peptide Antagonist of α4β7 Integrin, for the Treatment of Inflammatory Bowel Disease
Meeting: 5th Annual Macrocyclics and Constrained Peptides: Bigger, Better and Still Oral Small Molecules
Presenter: Ashok Bandari, Ph.D., Vice President, Chemistry, Protagonist Therapeutics 

Date and Time: 2:20 PM PT, Wednesday April 26

Share by:
×

Health Equity: Improving Access to Medicines, Ensuring Diverse Representation

Spotlight, Arturo Molina, MD, Chief Medical Officer

Dr. Molina, how are you helping to advance access to medicines?

At Protagonist, we work hard to meet the needs of the patient communities who are relying on us to innovate new and better medicines. Part of our commitment to them includes working to advance our medicines through clinical studies as quickly as possible and ensuring patients can access investigational therapies outside of our clinical trials, which has allowed some patients in critical need to access our therapies for several additional years after trials conclude.

We’re seeing a greater push for better representation in therapeutic innovation across the industry. How is Protagonist supporting diverse and equitable discovery and development?

Protagonist actively works to ensure we have strong patient representation in our clinical studies. We actively seek patients from across urban, suburban, and rural locations, from varying age groups and from among diverse backgrounds to ensure equitable patient representation in our study data.

We’re particularly concerned aging populations are left out of clinical studies, and we’re currently working to recruit older patients into our trials.